Dr. Lal Pathlabs
Ticker > Company >

Dr. Lal Pathlabs share price

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB BSE: 539524 SECTOR: Hospital & Healthcare Services  2.64 L   1.55 K   313

3324.00
+42.15 (1.28%)
BSE: 12 Sep 04:01 PM

Price Summary

Today's High

₹ 3347.95

Today's Low

₹ 3270.2

52 Week High

₹ 3645

52 Week Low

₹ 2295.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 27846.98 Cr.

Enterprise Value

₹ 27079.44 Cr.

No. of Shares

8.38 Cr.

P/E

52.8

P/B

12.62

Face Value

₹ 10

Div. Yield

0.72 %

Book Value (TTM)

₹  263.45

CASH

₹ 767.54 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

53.79 %

EPS (TTM)

₹  62.95

Sales Growth

10.66%

ROE

25.99 %

ROCE

31.99%

Profit Growth

43.42 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 26Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
48783.1
  292.299999999996 (0.602794756943581%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
45832.15
  272.800000000003 (0.598779394350446%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
45183.1
  172.699999999997 (0.38368910296287%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
26970.75
  40.9500000000007 (0.152062027939315%)

NIFTY500

Nifty 500
23190.25
  87.5999999999985 (0.379177280528409%)

NIFTY500LOWVOL50

Nifty500 Low Volatility 50 Index
22525.25
  88.1500000000015 (0.392876084699001%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19984.85
  58 (0.291064568659882%)

NIFTYSMALL

NIFTY Smallcap 100
17989.9
  114.700000000001 (0.641671142141065%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17832.35
  59.7999999999993 (0.336473944369264%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17144.85
  54.3499999999985 (0.318012931160583%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16163.75
  57.3999999999996 (0.356381178851817%)

NFT500EQUAL

Nifty 500 Equal Weight
14420.75
  39.0499999999993 (0.2715256193635%)

NIFTYTOTALMCAP

Nifty Total Market index
13051.25
  47 (0.361420304900317%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8647.7
  40.6000000000004 (0.47170359354487%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
53548.49
  146.110000000001 (0.273602037961607%)

BSE HC

S&P Bse Healthcare
44922.57
  120.980000000003 (0.270035059023588%)

BSE500

S&P Bse 500
36418.62
  130.709999999999 (0.360202612936367%)

BSE500QTY50

BSE 500 Quality 50
21882.43
  127.349999999999 (0.585380518021528%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12115.23
  24.6099999999988 (0.203546220127659%)

BSE1000

Bse 1000
10850.64
  36.4099999999999 (0.336686014630727%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SMLSEL

S&P Bse SmallCap Select Index
8048.65
  47 (0.587378853111553%)

SML250

S&P Bse 250 SmallCap
6862.99
  23.1899999999996 (0.33904500131583%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.66%
3 Year7.77%
5 Year13.05%

Profit Growth

1 Year43.42%
3 Year12.93%
5 Year17.38%

ROE%

1 Year25.99%
3 Year21.9%
5 Year23.65%

ROCE %

1 Year31.99%
3 Year27.18%
5 Year29.73%

Debt/Equity

0

Price to Cash Flow

51.57

Interest Cover Ratio

29.898

CFO/PAT (5 Yr. Avg.)

1.28920991536632

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 53.79 0.00
Mar 2025 53.91 0.00
Dec 2024 53.91 0.00
Sep 2024 53.92 0.00
Jun 2024 54.60 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 83.334 Cr.
  • Company has been maintaining healthy ROE of 21.8956333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.1777% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 29.898.
  • The Company has been maintaining an effective average operating margins of 27.2535199702361% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -129.6342 days.
  • Company has a healthy liquidity position with current ratio of 3.2883.
  • The company has a good cash flow management; CFO/PAT stands at 1.28920991536632.
  • The company has a high promoter holding of 53.79%.

 Limitations

  • The company has shown a poor revenue growth of 7.76946974408717% for the Past 3 years.
  • The company is trading at a high PE of 52.8.
  • The company is trading at a high EV/EBITDA of 34.9232.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 574.4 583.9 528.1 577.2 640.7
Total Expenditure 413.1 399.4 382.7 418.1 457.3
Operating Profit 161.3 184.5 145.4 159.1 183.4
Other Income 30.9 22 29.5 25.2 26.3
Interest 5.8 5 4.8 4.8 4.5
Depreciation 32.7 18.2 18.9 34.6 32.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 153.7 183.3 151.2 144.9 172.4
Tax 39.2 48.1 36.7 -3.5 43.1
Profit After Tax 114.5 135.2 114.5 148.4 129.3
Adjusted EPS (Rs) 13.71 16.17 13.7 17.75 15.43

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1490.56 1878.79 1769.03 2125.06 2351.62
Total Expenditure 1083.18 1366.32 1308.33 1544.45 1686.21
Operating Profit 407.38 512.47 460.7 580.61 665.41
Other Income 51.27 53.1 46.6 66.3 111.52
Interest 14.83 28.63 34.38 28.6 21.5
Depreciation 69.78 75.94 82.09 135.79 134.15
Exceptional Items 0 0 0 0 0
Profit Before Tax 374.04 460.99 390.83 482.53 621.28
Tax 93.94 115.74 98.47 135.8 124.02
Net Profit 280.11 345.25 292.36 346.73 497.26
Adjusted EPS (Rs.) 33.61 41.42 35.07 41.54 59.49

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 83.35 83.35 83.37 83.48 83.59
Total Reserves 1133.74 1388.77 1606.5 1717.24 2050.64
Borrowings 0 166.67 83.33 0 0
Other N/C liabilities 76.83 90.73 82.26 53.98 13.75
Current liabilities 252.25 451.04 432.16 450.47 388.44
Total Liabilities 1546.16 2180.55 2287.62 2305.18 2536.42
Assets
Net Block 300.07 370.95 361.48 1070.7 1017.83
Capital WIP 5.51 14.45 2.97 3.95 3.48
Intangible WIP 3.48 0 1.97 1.7 0
Investments 120.4 1061.81 1072.03 112.94 113.94
Loans & Advances 23.87 24.33 19.89 27.92 22.92
Other N/C Assets 3.53 9.71 19.11 51.57 100.98
Current Assets 1089.3 699.31 810.17 1036.39 1277.28
Total Assets 1546.16 2180.55 2287.62 2305.18 2536.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 374.04 460.99 390.83 482.53 621.28
Adjustment 59.1 87.81 96.31 120.22 74.79
Changes in Assets & Liabilities 37.33 -5.55 39.52 29.67 -1.44
Tax Paid -97.12 -117.53 -99.13 -127.82 -154.63
Operating Cash Flow 373.36 425.73 427.53 504.6 540
Investing Cash Flow -195.19 -448.53 -288.47 1.17 -293
Financing Cash Flow -135.74 141.24 -270.05 -410.53 -324.75
Net Cash Flow 42.42 118.43 -130.99 95.24 -77.75

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 54.60 53.92 53.91 53.91 53.79
anjaneya lal 2.02 2.02 2.02 2.02 2.02
archana lal erdmann 2.03 1.85 1.85 1.85 1.84
arvind lal - - - - 30.73
vandana lal 19.26 19.24 19.24 19.24 19.20
arvind lal 31.28 30.81 30.80 30.80 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 45.40 46.08 46.09 46.09 46.21
hdfc trustee company limi... 2.99 3.30 2.92 3.23 3.74
indus india fund (mauriti... - - - 1.02 1.04
invesco oppenheimer inter... 3.73 3.56 3.56 3.52 3.51
life insurance corporatio... 1.47 1.47 1.47 1.47 1.47
llp 0.03 0.03 0.02 0.02 0.02
nippon life india trustee... - - - 1.68 2.12
sbi large & midcap fund 1.01 1.76 1.65 1.70 1.70
smallcap world fund, inc - - 1.18 1.47 1.59
sundaram mutual fund a/c ... - - - - 1.12
tata balanced advantage f... - - - - 1.04
the brown capital managem... - - - 1.34 1.37
uti-flexi cap fund - - - 2.32 2.40
om prakash manchanda 1.08 1.04 1.01 - -
uti flexi cap fund 2.82 2.30 2.06 - -
first sentier investors i... 1.10 1.10 - - -
al mehwar commercial inve... 1.02 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research Prabhudas Lilladhar

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q4FY21
Concall Q4FY20
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY22
Concall Q2FY21
Concall Q1FY22
Concall Q1FY21
Concall Q1FY20
Concall Q3FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation Q3FY20

Company News

Dr. Lal PathLabs informs about press release 20 Aug, 11:52 AM Dr. Lal Pathlabs pioneers AI integration in cancer diagnosis in India 20 Aug, 11:43 AM Dr. Lal PathLabs informs about press release 1 Aug, 2:27 PM Dr. Lal PathLabs informs about record date 31 Jul, 5:30 PM Dr. Lal PathLabs informs about press release 31 Jul, 2:58 PM Dr. Lal PathLabs informs about investor presentation 31 Jul, 2:28 PM Dr. Lal Pathlabs - Quaterly Results 31 Jul, 1:25 PM Dr. Lal Pathlabs - Quaterly Results 31 Jul, 1:25 PM Dr. Lal Pathlabs - Quaterly Results 31 Jul, 1:25 PM Dr. Lal PathLabs informs about analyst meet 24 Jul, 5:06 PM Dr. Lal PathLabs informs about press release 25 Jun, 2:52 PM Dr. Lal PathLabs expands genomics capabilities with Illumina's NovaSeq X Series 25 Jun, 2:42 PM Dr. Lal PathLabs informs about annual report 4 Jun, 3:31 PM Dr. Lal PathLabs informs about BRSR 4 Jun, 2:19 PM Dr. Lal PathLabs informs about analyst meet 19 May, 12:03 PM Dr. Lal PathLabs informs about press release 8 May, 5:35 PM Dr. Lal PathLabs informs about newspaper publication 26 Apr, 12:29 PM Dr. Lal PathLabs informs about press release 26 Apr, 12:20 PM Dr. Lal PathLabs informs about AGM 25 Apr, 5:09 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal Pathlabs - Quaterly Results 25 Apr, 2:20 PM Dr. Lal PathLabs informs about press release 15 Apr, 2:25 PM Dr. Lal PathLabs launches test for Amyloidosis disease 15 Apr, 12:21 PM Dr. Lal PathLabs informs about trading window closure 25 Mar, 12:25 PM Dr. Lal PathLabs informs about postal ballot notice 7 Feb, 10:40 AM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal Pathlabs - Quaterly Results 30 Jan, 1:39 PM Dr. Lal PathLabs informs about conference call 24 Jan, 12:34 PM Dr. Lal PathLabs informs about allotment under ESOP 18 Dec, 3:19 PM Dr. Lal PathLabs informs about analyst meet 26 Nov, 1:02 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal Pathlabs - Quaterly Results 23 Oct, 3:38 PM Dr. Lal PathLabs informs about board meeting 16 Oct, 1:13 PM Dr. Lal PathLabs informs about closure of trading window 26 Sep, 12:54 PM Dr. Lal PathLabs informs about outcome of board meeting 13 Aug, 11:06 AM Dr. Lal PathLabs informs about transcript of earnings call 13 Aug, 11:03 AM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal Pathlabs - Quaterly Results 7 Aug, 3:08 PM Dr. Lal PathLabs submits board meeting intimation 31 Jul, 1:22 PM Dr. Lal PathLabs informs about newspaper advertisements 6 Jun, 3:48 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal Pathlabs - Quaterly Results 10 May, 1:40 PM Dr. Lal PathLabs informs about board meeting 3 May, 10:49 AM Dr. Lal PathLabs informs about closure of trading window 26 Mar, 2:59 PM Dr. Lal PathLabs informs about outcome of committee meet 18 Mar, 8:16 AM

Dr. Lal Pathlabs Stock Price Analysis and Quick Research Report. Is Dr. Lal Pathlabs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Dr. Lal Pathlabs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Dr. Lal Pathlabs has a PE ratio of 53.1165612987261 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Dr. Lal Pathlabs has ROA of 20.5413% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Dr. Lal Pathlabs has a Current ratio of 3.2883.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Dr. Lal Pathlabs has a ROE of 25.986%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Dr. Lal Pathlabs has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Dr. Lal Pathlabs has reported revenue growth of 10.661% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Dr. Lal Pathlabs for the current financial year is 28.2957031656968%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Dr. Lal Pathlabs is Rs 24 and the yield is 0.722%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Dr. Lal Pathlabs is Rs 62.954. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Dr. Lal Pathlabs in Ticker for free. Also, one can get the intrinsic value of Dr. Lal Pathlabs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Dr. Lal Pathlabs FAQs

Q1. What is Dr. Lal Pathlabs share price today?
Ans: The current share price of Dr. Lal Pathlabs is Rs 3343.9.

Q2. What is the market capitalisation of Dr. Lal Pathlabs?
Ans: Dr. Lal Pathlabs has a market capitalisation of Rs 28013.6927889 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Dr. Lal Pathlabs?
Ans: The PE ratio of Dr. Lal Pathlabs is 53.1165612987261 and the P/B ratio of Dr. Lal Pathlabs is 12.6926828897973, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Dr. Lal Pathlabs share?
Ans: The 52-week high share price of Dr. Lal Pathlabs is Rs 3653.95, and the 52-week low share price of Dr. Lal Pathlabs is Rs 2293.55.

Q5. Does Dr. Lal Pathlabs pay dividends?
Ans: Currently, Dr. Lal Pathlabs pays dividends. Dividend yield of Dr. Lal Pathlabs is around 0.722%.

Q6. What are the face value and book value of Dr. Lal Pathlabs shares?
Ans: The face value of Dr. Lal Pathlabs shares is Rs 10, while the book value per share of Dr. Lal Pathlabs is around Rs 263.451. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Dr. Lal Pathlabs?
Ans: Dr. Lal Pathlabs has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Dr. Lal Pathlabs?
Ans: The ROE of Dr. Lal Pathlabs is 25.986% and ROCE of Dr. Lal Pathlabs is 31.9926%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Dr. Lal Pathlabs a good buy for the long term?
Ans: The Dr. Lal Pathlabs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Dr. Lal Pathlabs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Dr. Lal Pathlabs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Dr. Lal Pathlabs’s financials?
Ans: You can review Dr. Lal Pathlabs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Dr. Lal Pathlabs

Dr. Lal Pathlabs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Dr. Lal Pathlabs Ltd. is a leading provider of diagnostic healthcare services in India. Long-term investors interested in investing in healthcare companies need to conduct a comprehensive stock analysis of Dr. Lal Pathlabs Ltd. The analysis should include essential factors like balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Dr. Lal Pathlabs Ltd. Share Price

The share price of Dr. Lal Pathlabs Ltd. is a crucial factor to consider when analyzing the company for long-term investment. The share price is influenced by various factors, including market trends, financial performance, and investor sentiment. Ticker pre-built screening tools provide real-time updates on the share price of Dr. Lal Pathlabs Ltd., helping investors stay informed about price fluctuations and market trends.

Dr. Lal Pathlabs Ltd. Balance Sheet

Analyzing the balance sheet of Dr. Lal Pathlabs Ltd. is essential to understand the financial stability and performance of the company. The balance sheet provides a snapshot of the company's assets, liabilities, and shareholders' equity. Dr. Lal Pathlabs Ltd.'s balance sheet is analyzed using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, allowing investors to calculate fair value based on the balance sheet.

Dr. Lal Pathlabs Ltd. Annual Report

Dr. Lal Pathlabs Ltd. annual report provides comprehensive details about the company's financial performance, strategic initiatives, and future prospects. Investors can access and download the annual report directly from Ticker to gain a deeper understanding of Dr. Lal Pathlabs Ltd.'s performance and make well-informed investment decisions.

Dr. Lal Pathlabs Ltd. Dividend

Dr. Lal Pathlabs Ltd. provides dividends as a way to share its profits with shareholders. Dividends are a crucial consideration for long-term investors, as they demonstrate the company's commitment to returning value to shareholders. By monitoring dividend payments through Ticker pre-built screening tools, investors can stay updated on the latest dividend announcements and assess the company's dividend history.

Dr. Lal Pathlabs Ltd. Quarterly Results

Analyzing the quarterly results of Dr. Lal Pathlabs Ltd. provides crucial information about the company's growth and profitability over specific periods. By monitoring revenue, expenses, and profits, investors can assess the company's performance and make informed investment decisions. Dr. Lal Pathlabs Ltd.'s financial information is analyzed using tools like Earnings multiple approaches and DuPont analysis, enabling long-term investors to make informed investment decisions.

Dr. Lal Pathlabs Ltd. Stock Price

The stock price of Dr. Lal Pathlabs Ltd. is influenced by various factors, including market trends, financial performance, and investor sentiment. Tracking the stock price helps investors gain insights into the market's reaction to the company's performance and news. Ticker pre-built screening tools provide real-time updates on the stock price of Dr. Lal Pathlabs Ltd., allowing investors to stay informed about price movements and make well-informed decisions.

Dr. Lal Pathlabs Ltd. Price Chart

The price chart of Dr. Lal Pathlabs Ltd. visually represents the historical trends of the stock price. By analyzing the chart, long-term investors can identify patterns and trends that may impact future stock performance. The price chart is a valuable tool for assessing the potential investment value of Dr. Lal Pathlabs Ltd. and making informed decisions.

Dr. Lal Pathlabs Ltd. News

Staying updated with the latest news about Dr. Lal Pathlabs Ltd. is crucial for long-term investors conducting a stock analysis. Ticker provides access to the company's news, including press releases, analyst reports, and market updates. This ensures investors can keep track of changes and developments in the company and make informed investment decisions.

Dr. Lal Pathlabs Ltd. Concall

Participating in Dr. Lal Pathlabs Ltd.'s concall allows investors to hear directly from the management team. The concall offers valuable insights into the company's financial performance, strategic initiatives, and future plans. Investors can access the transcripts of the concall on Ticker, enabling them to review and refer to the discussions.

Dr. Lal Pathlabs Ltd. Transcripts

The transcripts of Dr. Lal Pathlabs Ltd.'s concall provide a detailed account of the discussions between the management team, analysts, and investors. These transcripts contain valuable information that aids in investment analysis and decision-making.

Dr. Lal Pathlabs Ltd. Investor Presentations

Dr. Lal Pathlabs Ltd.'s investor presentations provide an in-depth overview of the company's operations, future prospects, and growth strategy. By reviewing these presentations, investors can gain insights into Dr. Lal Pathlabs Ltd.'s long-term plans and evaluate its potential as an investment opportunity.

Dr. Lal Pathlabs Ltd. Promoters

Identifying the promoters of Dr. Lal Pathlabs Ltd. provides insights into the management team's involvement and influence over the company. Understanding the promoters helps in analyzing the company's ownership structure and potential conflicts of interest.

Dr. Lal Pathlabs Ltd. Shareholders

Analyzing the shareholder base of Dr. Lal Pathlabs Ltd. provides investors with insights into the company's ownership structure. Understanding the distribution of shares among various shareholders helps assess its potential impact on the company's stock performance and governance.

Dr. Lal Pathlabs Ltd. ROCE

Dr. Lal Pathlabs Ltd's Return on Capital Employed (ROCE) is a fundamental metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page offers the ROCE data for Dr. Lal Pathlabs Ltd, enabling investors to assess the company's ability to generate returns on the capital employed. By analyzing this ratio, investors can understand the company's financial performance and make informed investment decisions. Access detailed information on Dr. Lal Pathlabs Ltd's ROCE in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. EBITDA

Dr. Lal Pathlabs Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a crucial measure for assessing the company's operational performance and profitability. By analyzing the company's core earnings, investors gain insights into its financial stability. Our stock analysis page provides comprehensive EBITDA data for Dr. Lal Pathlabs Ltd, allowing investors to evaluate the company's operational efficiency. You can find detailed EBITDA figures for Dr. Lal Pathlabs Ltd in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. DPS

Dr. Lal Pathlabs Ltd's Dividends Per Share (DPS) indicates the portion of profits distributed to shareholders in the form of dividends. Monitoring DPS is essential for investors seeking a consistent dividend income. On our stock analysis page, we present the DPS data for Dr. Lal Pathlabs Ltd, enabling investors to track the company's dividend history and payout ratio. You can find the detailed DPS information in the financials table or ratio section on our website.

Dr. Lal Pathlabs Ltd. EPS

Earnings Per Share (EPS) measures Dr. Lal Pathlabs Ltd's profitability on a per-share basis. By analyzing the company's EPS, investors can assess its earnings performance and growth potential. Our stock analysis page provides comprehensive EPS information for Dr. Lal Pathlabs Ltd, allowing investors to evaluate the company's profitability trends. Access the detailed EPS figures for Dr. Lal Pathlabs Ltd in the financials table or ratio section on our website to make informed investment decisions. 

Dr. Lal Pathlabs Balance Sheet Exploration

Dr. Lal Pathlabs' Sturdy Reserve Growth

The Standalone Balance Sheet of Dr. Lal Pathlabs exhibits a steadfast growth in total reserves, escalating from Rs. 932.94 Cr in March 2020 to Rs. 1,816.18 Cr by March 2024. This progression demonstrates the company's robust financial health and capacity for further expansion or debt reduction.

Effective Debt Management at Dr. Lal Pathlabs

Remarkably, Dr. Lal Pathlabs showcased prudent financial stewardship by clearing its borrowings, which were recorded at Rs. 166.67 Cr in March 2022, down to zero by March 2024. This maneuver evidences the company's strategic financial planning and commitment to operating without leveraging debt.

Asset Augmentation Strategies of Dr. Lal Pathlabs

With total assets amounting to Rs. 2,376.81 Cr by March 2024, Dr. Lal Pathlabs has adeptly matched its liabilities, underscoring its strategic asset growth, particularly in investments which stood at Rs. 1,072.80 Cr, and an uptick in current assets to Rs. 920.55 Cr, ensuring liquidity for operational efficiency.

Insightful Investment in Dr. Lal Pathlabs

The surge in investments to Rs. 1,072.80 Cr by March 2024 highlights Dr. Lal Pathlabs' focus on harnessing market opportunities to bolster long-term growth, reflecting a strategic vision towards enhancing shareholder value.

This analysis on Dr. Lal Pathlabs' Standalone Balance Sheet draws attention to its efficacious financial management, operational efficiency, and strategic investment moves aimed at fostering sustainable growth and stability.

Investors tracking the healthcare sector on NSE and BSE indices may find companies like Dr. Lal Pathlabs particularly intriguing for their consistent financial performance and strategic market positioning.

Read More
X